Development of camelid single chain antibodies against Shiga toxin type 2 (Stx2) with therapeutic potential against Hemolytic Uremic Syndrome (HUS)

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Mejías, Maria P ^a   Hiriart, Yanina ^b,c   Lauché, Constanza ^b,c   Fernández Brando, Romina J ^a   Pardo, Romina ^b,c   Bruballa, Andrea ^a   Ramos, María V ^a   Goldbaum, Fernando A ^b,c   Palermo, Marina S ^a   Zylberman, Vanesa ^b,c  

^a Consejo Nacional de Investigaciones Científicas y Técnicas ^*  (Argentina)

^b Gral San Martín   (Argentina)

^c FUNDACIÓN INSTITUTO LELOIR   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITOXIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VEROTOXIN 2;

ANIMAL; CAMEL; DISEASE MODEL; HEMOLYTIC UREMIC SYNDROME; IMMUNOLOGY; IMMUNOTHERAPY; ISOLATION AND PURIFICATION; MOUSE; PROCEDURES; SEROLOGY; TREATMENT OUTCOME;

ANIMALS; ANTITOXINS; CAMELUS; DISEASE MODELS, ANIMAL; HEMOLYTIC-UREMIC SYNDROME; IMMUNOTHERAPY; MICE; SEROLOGIC TESTS; SHIGA TOXIN 2; SINGLE-CHAIN ANTIBODIES; THERAPEUTICS; TREATMENT OUTCOME;

EID: 84964823086     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24913     Document Type: Article

References (48)

1. Kaper, J. B., Nataro, J. P. & Mobley, H. L. Pathogenic Escherichia coli. Nat Rev Microbiol 2(2), 123-140 (2004).
2. Caprioli, A., Morabito, S., Brugere, H. & Oswald, E. Enterohaemorrhagic Escherichia coli: emerging issues on virulence and modes of transmission. Vet Res 36(3), 289-311 (2005).
3. Hauswaldt, S. et al. Lessons Learned From Outbreaks of Shiga Toxin Producing Escherichia coli. Curr Infect Dis Rep 15(1), 4-9 (2013).
4. Rivas, M. et al. [The epidemiology of hemolytic uremic syndrome in Argentina. Diagnosis of the etiologic agent, reservoirs and routes of transmission]. Medicina (B Aires) 66 Suppl 3, 27-32 (2006).
5. Noel, J. M. & Boedeker, E. C. Enterohemorrhagic Escherichia coli: a family of emerging pathogens. Dig Dis 15(1-2), 67-91 (1997).
6. O'Brien, A. D. et al. Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis. Curr Top Microbiol Immunol 180, 65-94 (1992).
7. Schmidt, H. Shiga-toxin-converting bacteriophages. Res Microbiol 152(8), 687-695 (2001).
8. Fraser, M. E., Chernaia, M. M., Kozlov, Y. V. & James, M. N. Crystal structure of the holotoxin from Shigella dysenteriae at 2.5 A resolution. Nat Struct Biol 1(1), 59-64 (1994).
9. Melton-Celsa, A. R. & O'Brien, A. D. New Therapeutic Developments against Shiga Toxin-Producing Escherichia coli. Microbiol Spectr 2(5), doi: 10.1128/microbiolspec.EHEC-0013-2013 (2014).
10. Dowling, T. C. et al. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob Agents Chemother 49(5), 1808-1812 (2005).
11. Bitzan, M. et al. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother 53(7), 3081-3087 (2009).
12. Lopez, E. L. et al. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody, against Shiga-like toxin 2 in healthy adults and in pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother 54(1), 239-243 (2010).
13. Taylor, C. M., Bitzan, M. & Reymond, D. SHIGATEC: a Phase II study assessing monoclonal antibodies against Shiga toxin 1 and 2 in Shiga toxin-producing E. coli-infected children. Pediatr Nephrol 26, 1595-1596 (2011).
14. Hamers-Casterman, C. et al. Naturally occurring antibodies devoid of light chains. Nature 363(6428), 446-448 (1993).
15. Bird, R. E. et al. Single-chain antigen-binding proteins. Science 242(4877), 423-426 (1988).
16. Goldman, E. R. et al. Facile generation of heat-stable antiviral and antitoxin single domain antibodies from a semisynthetic llama library. Anal Chem 78(24), 8245-8255 (2006).
17. van der Linden, R. H. et al. Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies. Biochim Biophys Acta 1431(1), 37-46 (1999).
18. Mukherjee, J. et al. A novel strategy for development of recombinant antitoxin therapeutics tested in a mouse botulism model. PLos One 7(1), e29941 (2012).
19. Tremblay, J. M. et al. A single VHH-based toxin-neutralizing agent and an effector antibody protect mice against challenge with Shiga toxins 1 and 2. Infect Immun 81(12), 4592-4603 (2013).
20. Vance, D. J., Tremblay, J. M., Mantis, N. J. & Shoemaker, C. B. Stepwise engineering of heterodimeric single domain camelid VHH antibodies that passively protect mice from ricin toxin. J Biol Chem 288(51), 36538-36547 (2013).
21. Yang, Z. et al. A novel multivalent, single-domain antibody targeting TcdA and TcdB prevents fulminant Clostridium difficile infection in mice. J Infect Dis 210(6), 964-972 (2014).
22. Mukherjee, J. et al. Prolonged prophylactic protection from botulism with a single adenovirus treatment promoting serum expression of a VHH-based antitoxin protein. PLoS One 9(8), e106422 (2014).
23. Sheoran, A. S. et al. Adenovirus vector expressing Stx1/Stx2-neutralizing agent protects piglets infected with Escherichia coli O157:H7 against fatal systemic intoxication. Infect Immun 83(1), 286-291 (2015).
24. Louise, C. B. & Obrig, T. G. Specific interaction of Escherichia coli O157:H7-derived Shiga-like toxin II with human renal endothelial cells. J Infect Dis 172(5), 1397-1401 (1995).
25. Ling, H. et al. Structure of the Shiga-like toxin I B-pentamer complexed with an analogue of its receptor Gb3. Biochemistry 37(7), 1777-1788 (1998).
26. Mejias, M. P. et al. Immunization with a chimera consisting of the B subunit of Shiga toxin type 2 and brucella lumazine synthase confers total protection against Shiga toxins in mice. J Immunol 191(5), 2403-2411 (2013).
27. Mejias, M. P. et al. Protection of mice against Shiga toxin 2 (Stx2)-Associated damage by maternal immunization with a Brucella lumazine synthase-Stx2 B subunit chimera. Infect Immun 82(4), 1491-1499 (2014).
28. Wambura, W. C. Isolation and characterization of serum albumin specific nanobody: generic toll for drugs serum half-life extension. (Faculty of Science, Vrije Universiteit, 2012).
29. Fernandez, G. C. et al. Relevance of neutrophils in the murine model of haemolytic uraemic syndrome: mechanisms involved in Shiga toxin type 2-induced neutrophilia. Clin Exp Immunol 146(1), 76-84 (2006).
30. Fernandez-Brando, R. J. et al. Shiga toxin-producing Escherichia coli O157:H7 shows an increased pathogenicity in mice after the passage through the gastrointestinal tract of the same host. J Med Microbiol 61(Pt6), 852-859 (2012).
31. Fernandez-Brando, R. J. et al. Oral administration of Shiga toxin-producing Escherichia coli induces intestinal and systemic specific immune response in mice. Med Microbiol Immunol 203(3), 145-154 (2014).
32. Brando, R. J. et al. Renal damage and death in weaned mice after oral infection with Shiga toxin 2-producing Escherichia coli strains. Clin Exp Immunol 153(2), 297-306 (2008).
33. Takeda, T. et al. [Epidemiological study of hemolytic uremic syndrome associated with enterohemorrhagic Escherichia coli in Japan]. Nihon Rinsho 55(3), 693-699 (1997).
34. Ruggiero, A. et al. Paradoxical glomerular filtration of carbon nanotubes. Proc Natl Acad Sci USA 107(27), 12369-12374 (2010).
35. Gainkam, L. O. et al. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med 49(5), 788-795 (2008).
36. Tijink, B. M. et al. Improved tumor targeting of anti-epidermal growth factor receptor Nanobodies through albumin binding: taking advantage of modular Nanobody technology. Mol Cancer Ther 7(8), 2288-2297 (2008).
37. Vosjan, M. J. et al. Nanobodies targeting the hepatocyte growth factor: potential new drugs for molecular cancer therapy. Mol Cancer Ther 11(4), 1017-1025 (2012).
38. Harmsen, M. M., Van Solt, C. B., Fijten, H. P. & Van Setten, M. C. Prolonged in vivo residence times of llama single-domain antibody fragments in pigs by binding to porcine immunoglobulins. Vaccine 23(41), 4926-4934 (2005).
39. Sepulveda, J. et al. Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents. Infect Immun 78(2), 756-763 (2010).
40. Lovdal, T., Andersen, E., Brech, A. & Berg, T. Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver. J Cell Sci 113(Pt18), 3255-3266 (2000).
41. Council, N. R. Guide for the care and use of laboratory animals. (National Academies Press, Washington, DC, 2011).
42. Hassanzadeh-Ghassabeh, G., Saerens, D. & Muyldermans, S. Isolation of antigen-specific Nanobodies in Antibody Engineering, edited by R. E. Kontermann & S. Dübel (Springer Science & Business Media, 2010), Vol. 2.
43. Arbabi Ghahroudi, M. et al. Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Letters 414(3), 521-526 (1997).
44. Conrath, K. E. et al. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother 45(10), 2807-2812 (2001).
45. Lake, D. F., Bernstein, R. M., Schluter, S. F. & Marchalonis, J. J. Generation of diverse single-chain proteins using a universal (Gly4-Ser)3 encoding oligonucleotide. Biotechniques 19(5), 700-702 (1995).
46. Fernandez-Brando, R. J. et al. Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods. PLos One 6(4), e19136 (2011).
47. Van Rooijen, N. & Sanders, A. Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174(1-2), 83-93 (1994).
48. Alves-Rosa, F. et al. Treatment with liposome-encapsulated clodronate as a new strategic approach in the management of immune thrombocytopenic purpura in a mouse model. Blood 96(8), 2834-2840 (2000).